College of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330004, PR China.
Scientific and Technical Research Management Department, Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, 330004, PR China.
Pharmacol Res. 2020 Sep;159:104984. doi: 10.1016/j.phrs.2020.104984. Epub 2020 Jun 2.
The prevalence of nonalcoholic fatty liver disease (NAFLD) in the general population is estimated at 25 %, and there is currently no effective treatment of NAFLD. Although insulin resistance (IR) is not the only factor causing the pathogenesis of NAFLD, hepatic IR has a cause-effective relationship with NAFLD. Improving hepatic IR is a potential therapeutic strategy to treat NAFLD. This review highlights the molecular mechanisms of hepatic IR in the development of NAFLD. Available data on potential drugs including glucagon-like peptide 1 receptor (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR-γ/α/δ) agonists, farnesoid X receptor (FXR) agonists, etc. are carefully discussed.
非酒精性脂肪性肝病（NAFLD）在普通人群中的患病率估计为 25%，目前尚无有效的 NAFLD 治疗方法。尽管胰岛素抵抗（IR）不是导致 NAFLD 发病机制的唯一因素，但肝 IR 与 NAFLD 存在因果关系。改善肝 IR 是治疗 NAFLD 的一种潜在治疗策略。本综述强调了肝 IR 在 NAFLD 发展中的分子机制。详细讨论了包括胰高血糖素样肽 1 受体（GLP-1）激动剂、过氧化物酶体增殖物激活受体（PPAR-γ/α/δ）激动剂、法尼醇 X 受体（FXR）激动剂等在内的潜在药物的数据。
